---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-050724"
form_type: "8-K"
ticker: "AVIR"
cik: "0001593899"
company_name: "Atea Pharmaceuticals, Inc."
filed_at: "2024-02-28T23:59:59+00:00"
generated_at: "2026-06-05T08:52:21.871832+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Atea reports $136M FY2023 net loss; HCV Phase 2 confirms 98% SVR4; COVID-19 Phase 3 enrollment >1,400

## Summary
- Q4 net loss $39.2M ($0.47 diluted EPS) vs $34.4M loss in Q4 2022; FY net loss $136.0M ($1.63) vs $115.9M.
- Cash & marketable securities $578.1M at Dec 31, 2023, down from $646.7M at Dec 31, 2022.
- HCV Phase 2 lead-in final results: 98% SVR4 (58/59 patients); enrollment reinitiated for up to 220 patients, including cirrhotics.
- COVID-19 Phase 3 SUNRISE-3: >1,400 patients enrolled in monotherapy cohort; interim analyses expected March 2024 and Q2 2024.
- Topline results for SUNRISE-3 and HCV Phase 2 SVR12 both anticipated in H2 2024.

## SEC filing metadata
- accession: 0001193125-24-050724
- form_type: 8-K
- ticker: AVIR
- cik: 0001593899
- company_name: Atea Pharmaceuticals, Inc.
- filed_at: 2024-02-28T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1593899/000119312524050724/0001193125-24-050724-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1593899/000119312524050724/d791287d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-050724
- JSON: https://secwatch.observer/filing/0001193125-24-050724.json
- Plain text: https://secwatch.observer/filing/0001193125-24-050724.txt

## Key facts
- Earnings Releases
  Atea Pharmaceuticals, Inc. reported financial results for the fourth quarter and full year ended December 31, 2023.
  - Period: the fourth quarter and full year ended December 31, 2023
  - Result: reported results
  source text: Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided a business update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1593899/000119312524050724/0001193125-24-050724-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.